A Confirmatory Study of MP-513 for Treatment of Type 2 Diabetes in Randomized, Double-Blind, Parallel Assignment, Placebo-Controlled Manner.
Phase of Trial: Phase II
Latest Information Update: 14 Oct 2015
At a glance
- Drugs Teneligliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 02 Feb 2009 Additional lead trial investigator identified as reported by ClinicalTrials.gov, last updated 2 Feb 2009
- 02 Feb 2009 Actual patient numbers (324) added as reported by ClinicalTrials.gov.